未登录

J

Julia R. Trosman

healthcare

H指数:21

被引数:1,251

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Improving timing and sequencing of postoperative radiation therapy in head and neck cancer

改善头颈癌术后放射治疗的时机与顺序

IF2.7

2026-03-260

PRE

Comparing VA and safety-net hospital patient-reported care metrics and provider recommendations to address social determinants of health and demographics

CANCER RESEARCH

IF16.6

2024-03-220

PRE

LGBTQ cancer care: Assessing the benefits and limitations of a novel cancer care coordination tool

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

IF3.4

2022-01-010

PRE

US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER)

美国私人付款人对基因组测序与外显子组测序保险范围的看法: 临床测序证据生成研究联盟 (CSER) 的一项研究

GENETICS IN MEDICINE

IF6.2

2022-01-019

OAAI

Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

IF16.4

2021-03-0121

OA

Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019

来自2015个2019年的美国私人付款人肿瘤测序覆盖率增加的时间评估的见解

VALUE IN HEALTH

IF6

2020-05-0110

OAAI

Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS)

GENETICS IN MEDICINE

IF6.2

2020-02-0149

OAAI

Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IF55

2019-06-2516

OAAI

Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer Patients

创新癌症护理服务: 结直肠癌患者的4R肿瘤学模型示例

CURRENT TREATMENT OPTIONS IN ONCOLOGY

IF4.7

2019-02-114

PREAI

Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited

GENETICS IN MEDICINE

IF6.2

2019-01-0129

OAAI

From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing

从过去到现在: 下一代肿瘤测序的保险公司覆盖框架

VALUE IN HEALTH

IF6

2018-09-0121

OAAI

The evolution of patient navigation research models to reduce breast cancer disparities: Case studies of patient navigation dissemination and implementation in Chicago

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Payer coverage policies for multigene tests

NATURE BIOTECHNOLOGY

IF41.7

2017-07-0141

OAAI

Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening

GENETICS IN MEDICINE

IF6.2

2017-05-0119

OAAI

Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

IF16.4

2017-02-1038

OAAI

Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies

VALUE IN HEALTH

IF6

2017-01-0118

OAAI

What Goes Around Comes Around: Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine

VALUE IN HEALTH

IF6

2017-01-0112

OAAI

Radiology as the Point of Cancer Patient and Care Team Engagement: Applying the 4R Model at a Patient's Breast Cancer Care Initiation

JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY

IF5.1

2016-12-0112

OAAI

Availability and payer coverage of BRCA1/2 tests and gene panels

NATURE BIOTECHNOLOGY

IF41.7

2015-09-0124

OAAI

Challenges of Coverage Policy Development for Next-Generation Tumor Sequencing Panels: Experts and Payers Weigh In

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

IF16.4

2015-03-0339

OAAI